Abstract
Background:Salmonella and Shigella spp. are 2 of the most frequent and deadly enteric bacterial pathogens recorded worldwide. In developing countries Salmonella infections are responsible for many deaths annually and these mortality rates are prone to increase due to the emergence of resistance to antibiotics. In this overall scenario new alternative therapeutic approaches are needed.Methods:For the first time, we investigated the activity of 3 commercial bacteriophage cocktails (INTESTI, Septaphage, PYO) against a collection of contemporary Salmonella spp. (n = 30) and Shigella spp. (n = 20) strains isolated in Switzerland. Phage susceptibility was determined by implementing the spot test.Results:The overall susceptibility of Salmonella spp. to INTESTI and Septaphage was 87% and 77%, respectively. With regard to Shigella spp., the overall susceptibility to INTESTI and Septaphage was 95% and 55%, respectively. PYO was observed to be active against only 10% of Salmonella spp. but against 95% of Shigella spp.Conclusions:Our results seem promising, especially for the INTESTI biopreparation against Salmonella enterica infections. Nevertheless, such speculation should be supported by further in vivo studies to confirm efficacy and safety of the cocktails. We also emphasize the importance of large in vitro screening analyses aimed to assess the activity of such biopreparations against contemporary multidrug-resistant strains that are emerging worldwide.
Highlights
Salmonella and Shigella spp. are the most frequently found and deadly enteric bacterial pathogens
In developing countries Salmonella infections are responsible for 1 million deaths annually and these mortality rates are likely to increase due to the emergence of resistance to commonly implemented antibiotics [5, 6]
For the first time, we explored the in vitro activity of 3 commercially available bacteriophage cocktails currently implemented in the country of Georgia to treat human intestinal infections
Summary
Salmonella and Shigella spp. are the most frequently found and deadly enteric bacterial pathogens. In developing countries Salmonella infections are responsible for 1 million deaths annually and these mortality rates are likely to increase due to the emergence of resistance to commonly implemented antibiotics [5, 6]. In this overall scenario, new alternative and cost-effective therapeutic approaches are needed. In developing countries Salmonella infections are responsible for many deaths annually and these mortality rates are prone to increase due to the emergence of resistance to antibiotics In this overall scenario new alternative therapeutic approaches are needed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
